As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
10 Analysts have issued a LAVA Therapeutics NV forecast:
10 Analysts have issued a LAVA Therapeutics NV forecast:
Mar '25 |
+/-
%
|
||
Revenue | 12 12 |
4%
4%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -58 -58 |
91%
91%
|
EBIT (Operating Income) EBIT | -58 -58 |
83%
83%
|
Net Profit | -49 -49 |
72%
72%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Head office | Netherlands |
CEO | Stephen Hurly |
Employees | 34 |
Founded | 2016 |
Website | www.lavatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.